| Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. | |
| | |
MedLine Citation:
|
PMID: 20605207 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context. |
| | |
Authors:
|
Franck E Nicolini; Sandrine Hayette; Laurence Legros; Philippe Rousselot; Frédéric Maloisel; Michel Tulliez; Agnès Guerci; Aude Charbonnier; Thomas Prébet; Françoise Rigal-Huguet; Kaddour Chabane; Jean-Pierre Magaud; Carole Paillet; Christine Pivot; Mauricette Michallet |
Related Documents
:
|
15160927 - Chronic myeloid leukemia in an adolescent with ollier's disease after intensive x-ray e... 8535217 - Acute monocytic leukemia: a single institution experience. 6959957 - Analysis of the breakpoints in translocation (15;17) observed in 4 patients with acute ... 20799577 - Ambiguous genitalia in neonates: a 4-year prospective study in a localized area. 19264737 - Basal ganglia and internal capsule stroke in childhood--risk factors, neuroimaging, and... 11310377 - Profile of hypertension in elderly subjects. |
Publication Detail:
|
Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study Date: 2010-06-03 |
Journal Detail:
|
Title: Leukemia research Volume: 35 ISSN: 1873-5835 ISO Abbreviation: Leuk. Res. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-20 Completed Date: 2011-01-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7706787 Medline TA: Leuk Res Country: England |
Other Details:
|
Languages: eng Pagination: 80-6 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Département d'hématologie clinique, hôpital Edouard Herriot, Lyon, France. franck-emmanuel.nicolini@chu-lyon.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antineoplastic Agents / administration & dosage*, adverse effects, therapeutic use Humans Interferon Alfa-2a / administration & dosage*, adverse effects, therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*, genetics, pathology Middle Aged Piperazines / administration & dosage*, adverse effects, therapeutic use Polyethylene Glycols / administration & dosage*, adverse effects, therapeutic use Pyrimidines / administration & dosage*, adverse effects, therapeutic use Remission Induction* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Piperazines; 0/Polyethylene Glycols; 0/Pyrimidines; 0/peginterferon alfa-2a; 152459-95-5/imatinib; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The down regulation of target genes by photo activated DNA nanoscissors.
Next Document: ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma...